GC Genome Corp
GC Genome Corp provides pharmaceutical and biotechnology services, primarily generating revenue through its operations in the healthcare sector.
Business. GC Genome Corp (340450.KQ) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm is headquartered in South Korea and is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GC Genome Corp (340450.KQ) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm is headquartered in South Korea and is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
GC Genome Corp has a market capitalization of 161.8 billion KRW, with a market price of 6,840 KRW per share. The company reported a revenue of 5.75 billion KRW in the latest period, but it remains unprofitable, with a net loss of 627.5 million KRW and an operating loss of 797.6 million KRW. Despite the net loss, the company generated positive operating cash flow of 384.3 million KRW, though free cash flow was negative at -16.99 million KRW. Capital expenditures amounted to 209.3 million KRW, indicating ongoing investment in infrastructure.
Profitability metrics show a gross margin of 44.75% (2.58 billion KRW gross profit on 5.75 billion KRW revenue), but the company's operating margin is negative at -13.87%. Return on invested capital (ROIC) and return on equity (ROE) are not available due to the lack of balance sheet data. These metrics fall below the industry median for profitability in the Biotechnology sector, where positive operating margins are typically expected.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. This lack of diversification increases exposure to sector-specific risks. No major geographic markets are disclosed, and the company does not report revenue by region or product line.
Looking ahead, the company is expected to see a 23.8% increase in revenue to 39 billion KRW in the next fiscal year, according to analyst estimates. However, the operating loss is expected to narrow, and EBIT is projected to reach 4 billion KRW. These projections suggest a potential turnaround, though the company remains unprofitable in the near term.
The company's risk profile is marked by low dilution risk and an inability to assess liquidity risk due to the absence of balance sheet data. No going-concern language is present in the source documents, and the company has not issued any recent equity or debt that would suggest dilution pressure. However, the lack of liquidity data raises concerns about the company's ability to meet short-term obligations.
Recent filings and transcripts do not indicate any major corporate events or strategic shifts. The company has not disclosed any significant partnerships, product launches, or regulatory changes that would impact its operations. Analysts remain cautiously optimistic, with the mean EPS estimate for the next period at 229 KRW, compared to the actual 185 KRW in the previous period.
- GC Genome Corp is unprofitable but generates positive operating cash flow despite a net loss.
- The company's gross margin is strong at 44.75%, but its operating margin is negative at -13.87%.
- Revenue is expected to grow by 23.8% in the next fiscal year, with EBIT projected to reach 4 billion KRW.
- The company has low dilution risk and no recent equity or debt issuance.
- Liquidity risk cannot be assessed due to the absence of balance sheet data.
- The company's business is concentrated in a single segment, increasing sector-specific risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue KRW 31.53B, +21,8% YoY; Operating income +175,8% YoY.
- ▍Revenue KRW 31.53B, +21,8% YoY
- ▍Operating income +175,8% YoY
- ▍Net income +421,8% YoY
- ▍Free cash flow +323,9% YoY
- ▍Net margin 12.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 229,00 |
| Revenue | —no estimate | —no estimate | 39,0B KRW |
| Operating income | —no estimate | —no estimate | 4,0B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Capex To Revenuecapital_expenditure / revenue
- Cash Conversion Ratiooperating_cash_flow / net_income
- GC Genome Corp Market data — financials · 2026-05-26
- GC Genome Corp Market data — analyst estimates · 2026-05-26